Transforming the genome to drug discovery

Drug Discovery Today

Volumn 7, Issue 11, 2002, Pages 583-584

  Murcko, Mark ^a   Caron, Paul ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

BIOTECHNOLOGY; DRUG DESIGN; DRUG INDUSTRY; DRUG SPECIFICITY; EDITORIAL; GENE SEQUENCE; GENOME; MEDICAL RESEARCH; MULTIGENE FAMILY; PROTEIN FAMILY; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; HUMAN;

DRUG DESIGN; GENOME, HUMAN; HUMAN; HUMANS;

EID: 0036591868     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02267-5     Document Type: Editorial

References (9)

1. Journey to the center of biology
2. The role of innovation in drug development
3. Chemogenomic approaches to drug discovery
4. Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era
5. Forecasting roles of combinatorial chemistry in the age of genomically derived drug discovery targets
6. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
7. Molecular basis for p38 protein kinase inhibitor specificity
8. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase
9. Acquisition of sensitivity of stress-activiated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket